JWH-373

JWH-373

0JWH-373 is a synthetic cannabinoid from the JWH series. It was developed by the team led by John W. Huffman, an organic chemist who was at Clemson University. JWH-373 acts as a potent and selective CB2 receptor agonist, with a Ki of 22.0 nM and a selectivity of around 200 times for CB2 over CB1 receptors.

History

JWH-373 is part of the JWH series of synthetic cannabinoids, named after John W. Huffman. The series was developed in the 1990s and early 2000s in the research labs of Clemson University. The aim of the research was to develop new therapeutic agents for use in the treatment of pain and inflammatory diseases.

Pharmacology

JWH-373 is a potent and selective agonist for the CB2 receptor. The CB2 receptor is primarily found in the immune system, and is less prevalent in the brain than the CB1 receptor. Activation of the CB2 receptor leads to anti-inflammatory and potentially analgesic effects.

JWH-373 has a Ki of 22.0 nM at the CB2 receptor, and is around 200 times more selective for CB2 over CB1. This makes it one of the more selective compounds in the JWH series.

Legal Status

The legal status of JWH-373 varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other synthetic cannabinoids which have been associated with illicit use.

See Also

• JWH-018
• JWH-073
• JWH-200
• Cannabinoid receptor
• Synthetic cannabinoids

References

‎